Investigation of the metabolism and toxicokinetics of the surfactant 2,4,7,9-tetramethyl-5-decyne-4,7-diol (TMDD) in humans

Investigation of the metabolism and toxicokinetics of the surfactant 2,4,7,9-tetramethyl-5-decyne-4,7-diol (TMDD) in humans - TMDD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00022825

Enrollment

Registered

2020-10-30

Start date

2020-11-12

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Exposition of humans with TMDD

Interventions

Group 1: Single oral dosage 0,075 mg/kg bw

Single dermal dosage 0,75 mg/kg bw of a solution containing 5% TMDD

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Healthy

Exclusion criteria

Exclusion criteria: Allergic persons expectant mothers breast-feeding mothers

Design outcomes

Primary

Measure	Time frame
Identification of major metabolites of TMDD in human urine	—

Secondary

Measure	Time frame
Toxicokinetics of the test compound and its major metabolites. By means of urine samples within 72 h after application	—

Countries

Germany

Contacts

Public ContactGerhard Scherer

ABF Analytisch-Biologisches Forschungslabor GmbH

gerhard.scherer@abf-lab.com+4989535395

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026